Syenza News — health technology assessment, market access and health economics

Ivonescimab Complete Response Letter: FDA Lists Four Reasons
The FDA complete response letter for ivonescimab (BLA 761524) cites China-heavy trial data, a modest PFS gain and the need for a new multiregional trial. Summit must resubmit or take another action within one year.
Recent Posts

EU Medical Device Reform Only Partly Fixes Rules for AI-Enabled Medical Devices
Nov 18
FDA Launches Global Reliance Disclosure Program for Approval Packages
Nov 18
Three-Month Dapivirine Vaginal Ring Receives Positive EMA Opinion
Nov 17
Povorcitinib for Hidradenitis Suppurativa: CHMP Recommends Povofortay
Nov 17
FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap
Nov 17Syenza's Top Picks

Zepbound and Foundayo telehealth access via Hims & Hers
Nov 9, 2026
Artificial Intelligence in Medicine Regulation: From Concept to Practice
Nov 12, 2026
EMA Draft Guideline on Predictive Biomarker Assays Opens Public Consultation to 31 March 2027
Nov 12, 2026
FDA Adds Warning on NAION Risk with GLP-1 Receptor Agonists
Nov 10, 2026
Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo
Nov 10, 2026
Neuquén Health Technology Assessment Agency: What Law 3563 Sets Up
Nov 10, 2026Latest News

Clinical Practice
EMA Recommends Gazyvaro for Systemic Lupus Erythematosus: What the Trial Shows
EMA recommends Gazyvaro for systemic lupus erythematosus after a 303-patient trial showed 76.7% response on add-on therapy versus 53.5% on placebo.

Artificial Intelligence And Machine Learning
Learning Health System Frameworks and AI in US Care: A Scoping Review
A scoping review of 54 learning health system framework studies and 31 AI studies in US care finds that AI work mostly stops at turning data into knowledge. Only three AI studies reached practice, and none described feedback from deployment back into the model. #SyenzaNews #MarketAccess

Clinical Practice
NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer
NICE draft guidance recommends Cytosponge and EndoSign to help detect oesophageal cancer and Barrett’s oesophagus. The tests need no sedation and can be done outside hospital. #SyenzaNews #MarketAccess #HealthTech

Cardiovascular And Metabolic Diseases
CHMP November 2026 Recommends Seven New Medicines for Approval
EMA’s CHMP recommended seven new medicines and 11 indication extensions at its 9 to 12 November 2026 meeting, and confirmed two refusals after re-examination.

Cardiovascular And Metabolic Diseases
Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet
The CHMP recommended granting a marketing authorisation for AstraZeneca’s Baxfendy (baxdrostat) for insufficiently controlled hypertension. The European Commission makes the final decision. #SyenzaNews #MarketAccess

Healthcare Spending Free account
NHLS Governance Crisis Reaches Parliament With R1.8 Billion in Irregular Spending
The NHLS governance crisis reached Parliament with R1.8 billion in irregular spending, an interim board and a disputed IP Capital consultancy.

Clinical Guidelines And Protocols
Appropriate Comparator Use for EMA-Approved Drugs Fell From 2011 to 2024
Only 58% of EMA-approved drug indications from 2011 to 2024 had at least one trial population tested against an appropriate comparator. The share fell from 78% of 2011 to 2012 approvals to 39% of 2023 to 2024 approvals. #SyenzaNews #MarketAccess

Clinical Guidelines And Protocols
ACS Updates Prostate Cancer Screening Guideline for PSA Testing
“The American Cancer Society has updated its prostate cancer screening guideline, with regular PSA testing for average-risk men aged 50 to 69.” #SyenzaNews #ProstateCancer

Health Policy
SADC Pharmaceutical Pooled Procurement Charter Signed in Durban
The Charter establishing the SADC Pharmaceuticals Pooled Procurement Services was signed in Durban on 12 November 2026, with Tanzania the first Member State to sign. #SyenzaNews #MarketAccess

Clinical Practice
Aspen Gets Approval for Generic Semaglutide in Brazil and South Africa
Aspen Pharmacare has received approval for generic semaglutide in Brazil and South Africa, following Canada in July. Launches in all three markets are expected over the coming months. #SyenzaNews #MarketAccess
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.




